CORD-19:c654596857bce9cdd64ffc51842048643107348c / 480819-481020 JSONTXT

Annnotations TAB JSON ListView MergeView

    CORD-19-Sentences

    {"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T4109","span":{"begin":0,"end":71},"obj":"Sentence"},{"id":"TextSentencer_T4110","span":{"begin":72,"end":201},"obj":"Sentence"},{"id":"T30282","span":{"begin":0,"end":71},"obj":"Sentence"},{"id":"T32271","span":{"begin":72,"end":201},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"University of Bonn, Pharmaceutical Microbiology, Bonn, Germany Purpose: The intravenous form (IV) of 400 mg Moxifloxacin (MOX), one of the newer fluoroquinolones, has been recently approved by the FDA."}

    Epistemic_Statements

    {"project":"Epistemic_Statements","denotations":[{"id":"T610","span":{"begin":0,"end":201},"obj":"Epistemic_statement"}],"text":"University of Bonn, Pharmaceutical Microbiology, Bonn, Germany Purpose: The intravenous form (IV) of 400 mg Moxifloxacin (MOX), one of the newer fluoroquinolones, has been recently approved by the FDA."}

    CORD-19_Custom_license_subset

    {"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T281","span":{"begin":0,"end":71},"obj":"Sentence"},{"id":"T282","span":{"begin":72,"end":201},"obj":"Sentence"}],"text":"University of Bonn, Pharmaceutical Microbiology, Bonn, Germany Purpose: The intravenous form (IV) of 400 mg Moxifloxacin (MOX), one of the newer fluoroquinolones, has been recently approved by the FDA."}